Table 1. Published сlinical cases follow-up after the resumption of imatinib therapy after acute imatinib hepatitis of CML patients .

CML, chronic myeloid leukemia

Authors, publication year	Clinical case
The resumption of the imatinib therapy with the recurrence of hepatotoxicity
James C. and co-authors (2003) [5]		Recurring imatinib hepatitis in both cases with the restarting imatinib therapy
Rocca P. and co-authors (2004) [6]		Imatinib hepatitis recurring in two weeks after the restarting imatinib therapy
Sobhi E. and co-authors (2007) [7]		Imatinib hepatitis worsening again during the restarting three weeks later resumption imatinib therapy
Ikuta K. and co-authors (2005) [8]		Recurring hepatoxicity upon the restarting imatinib therapy at a low dose
The resumption of the imatinib therapy without the recurrence of hepatotoxicity
Ikuta K. and co-authors (2005) [8]		Hepatoxicity did not recur when prednisone (20 mg/day) was given. Later it was tapered and stopped, then there was the resumption of the imatinib therapy without the development of the hepatotoxicity
Ferrero D. and co-authors (2006) [9]		The resumption of the full dose imatinib while corticosteroids were gradually discontinued after three-five months without the recurrence of the hepatotoxicity (five clinical cases were described).
Kang B.W. and co-authors (2009) [10]		The acute imatinib hepatitis and hepatitis B reactivation required the liver transplantation. The patient was treated with lamivudine and seven months after the transplantation imatinib was restarted without further complications
Wang Y.D. and co-authors (2012) [11]		Symptomatic reactivation of hepatitis B in 40-year-old man six months after the starting of the imatinib therapy for CML responding to entecavir and able to continue imatinib
Lai G.-M. and co-authors (2013) [12]		Two cases of hepatitis B reactivation in CML patients receiving imatinib responded to the therapy with entecavir and the resumed therapy with the imatinib therapy